Management of Infectious Mononucleosis in Paediatric Athletes
DOI:
https://doi.org/10.12775/QS.2026.54.70876Keywords
mononucleosis, Epstein-Barr virus, return to play, paediatric athletes, sports medicineAbstract
Background. Infectious mononucleosis (IM), most commonly caused by the Epstein–Barr virus (EBV), affects primarily adolescents and young adults between 15 and 24 years of age, populations with high rates of sports participation. Although IM is usually self-limited, ,its symptoms most often include fever, pharyngitis, posterior cervical lymphadenopathy, fatigue, and malaise.
Aim of study. This review aims to summarize the current evidence on the diagnosis, clinical management, and return to play (RTP) recommendations for athletes and paediatric athletes with IM.
Materials and Methods. The review was based on a search of articles published in the PubMed database. Search terms included: infectious mononucleosis, Epstein-Barr virus, splenic rupture, splenomegaly, return to play and Monospot test
Current state of knowledge. Prolonged fatigue and the risk of splenic rupture may significantly disrupt training and competition. The most relevant sports-related complication is splenic rupture, which is associated with splenomegaly and occurs most often early in the disease course.
Conclusions. RTP decisions should be individualized based on symptom resolution, clinical findings, the type of sport (contact vs non-contact), and shared decision-making. The general consensus is to avoid contact sports and strenuous training for at least 3–4 weeks. Ultrasound may be helpful in selected cases, but its routine use is limited by the wide variability in baseline spleen size and the absence of validated thresholds for safe RTP.
References
[1] J. de M. Silva, C. E. de C. Alves, and G. S. Pontes, “Epstein-Barr virus: the mastermind of immune chaos,” Front. Immunol., vol. 15, p. 1297994, 2024, doi: 10.3389/FIMMU.2024.1297994.
[2] M. Mohseni, M. P. Boniface, and C. Graham, “Mononucleosis,” Prim. Care Update Ob. Gyns., vol. 2, no. 5, pp. 152–156, Aug. 2023, doi: 10.1016/1068-607X(95)00034-5.
[3] A. K. C. Leung, J. M. Lam, and B. Barankin, “Infectious Mononucleosis: An Updated Review,” Curr. Pediatr. Rev., vol. 20, no. 3, pp. 305–322, Aug. 2024, doi: 10.2174/1573396320666230801091558.
[4] H. H. Balfour and M. R. Meirhaeghe, “Infectious Mononucleosis,” Curr. Top. Microbiol. Immunol., 2025, doi: 10.1007/82_2025_286.
[5] A. Fugl and C. L. Andersen, “Epstein-Barr virus and its association with disease - a review of relevance to general practice,” BMC Fam. Pract., vol. 20, no. 1, p. 62, May 2019, doi: 10.1186/S12875-019-0954-3.
[6] S. Aldulaimi and A. M. Mendez, “Splenomegaly: Diagnosis and Management in Adults,” Am. Fam. Physician, vol. 104, no. 2, pp. 271–276, Sep. 2021, Accessed: Feb. 22, 2026. [Online]. Available: https://www.aafp.org/pubs/afp/issues/2021/0900/p271.html
[7] J. A. Becker and J. A. Smith, “Return to play after infectious mononucleosis,” Sports Health, vol. 6, no. 3, pp. 232–238, May 2014, doi: 10.1177/1941738114521984.
[8] L. I. Levin, K. L. Munger, E. J. O’Reilly, K. I. Falk, and A. Ascherio, “Primary infection with the Epstein-Barr virus and risk of multiple sclerosis,” Ann. Neurol., vol. 67, no. 6, pp. 824–830, Jun. 2010, doi: 10.1002/ANA.21978.
[9] A. S. Ceraulo and J. R. Bytomski, “Infectious Mononucleosis Management in Athletes,” Clin. Sports Med., vol. 38, no. 4, pp. 555–561, Oct. 2019, doi: 10.1016/J.CSM.2019.06.002.
[10] H. H. Balfour, S. K. Dunmire, and K. A. Hogquist, “Infectious mononucleosis,” Clin. Transl. Immunology, vol. 4, no. 2, p. e33, Feb. 2015, doi: 10.1038/CTI.2015.1.
[11] S. K. Dunmire, K. A. Hogquist, and H. H. Balfour, “Infectious Mononucleosis,” Curr. Top. Microbiol. Immunol., vol. 390, p. 211, 2015, doi: 10.1007/978-3-319-22822-8_9.
[12] N. D. Stuempfig and J. Seroy, “Monospot Test,” StatPearls, Aug. 2023, Accessed: Jan. 17, 2026. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK539739/
[13] S. K. Dunmire, P. S. Verghese, and H. H. Balfour, “Primary Epstein-Barr virus infection,” Journal of Clinical Virology, vol. 102, pp. 84–92, May 2018, doi: 10.1016/J.JCV.2018.03.001.
[14] E. B. SMITH and R. P. CUSTER, “Rupture of the Spleen in Infectious Mononucleosis: A Clinicopathologic Report of Seven Cases,” Blood, vol. 1, no. 4, pp. 317–333, Jul. 1946, doi: 10.1182/BLOOD.V1.4.317.317.
[15] R. J. Shephard, “Exercise and the Athlete With Infectious Mononucleosis,” Clin. J. Sport Med., vol. 27, no. 2, pp. 168–178, Mar. 2017, doi: 10.1097/JSM.0000000000000330.
[16] A. Bartlett, R. Williams, and M. Hilton, “Splenic rupture in infectious mononucleosis: A systematic review of published case reports,” Injury, vol. 47, no. 3, pp. 531–538, 2016, doi: 10.1016/J.INJURY.2015.10.071.
[17] M. S. Durtschi, N. S. Pham, and C. E. Hwang, “Liver Function Test Results Correlate With Spleen Size in Patients With Infectious Mononucleosis,” Cureus, vol. 16, no. 9, p. e70041, Sep. 2024, doi: 10.7759/CUREUS.70041.
[18] D. G. Maki and R. M. Reich, “Infectious mononucleosis in the athlete,” Am. J. Sports Med., vol. 10, no. 3, pp. 162–173, 1982, doi: 10.1177/036354658201000308.
[19] M. M. Asgari and D. G. Begos, “Spontaneous splenic rupture in infectious mononucleosis: a review,” Yale J. Biol. Med., vol. 70, no. 2, p. 175, Mar. 1997, Accessed: Feb. 26, 2026. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC2589064/
[20] R. G. Hosey, V. Kriss, T. L. Uhl, J. Difiori, S. Hecht, and D. Y. Wen, “Ultrasonographic evaluation of splenic enlargement in athletes with acute infectious mononucleosis,” Br. J. Sports Med., vol. 42, no. 12, pp. 974–977, Dec. 2008, doi: 10.1136/BJSM.2008.050807.
[21] N. L. Kensey and J. Higgs, “‘Kissing tonsils’ and splenic infarction from infectious mononucleosis,” Cleve. Clin. J. Med., vol. 90, no. 8, pp. 463–464, Aug. 2023, doi: 10.3949/CCJM.90A.22079.
[22] A. Hajri et al., “Spontaneous splenic rupture: A rare complication of acute myeloid leukemia. Report of a case,” Annals of Medicine and Surgery, vol. 65, p. 102286, May 2021, doi: 10.1016/J.AMSU.2021.102286.
[23] G. K. Seng, I. Ullah, K. P. Manning, and J. E. Fenton, “Spontaneous Splenic Rupture in Infectious Mononucleosis,” Ear Nose Throat J., vol. 86, no. 5, pp. 300–301, 2007, doi: 10.1177/014556130708600518.
[24] J. M. A. Toti et al., “Splenic rupture or infarction associated with Epstein-Barr virus infectious mononucleosis: a systematic literature review,” Swiss Med. Wkly., vol. 153, no. 5, pp. 40081–40081, May 2023, doi: 10.57187/SMW.2023.40081.
[25] I. Kazama, C. Miura, and T. Nakajima, “Nonsteroidal Anti-Inflammatory Drugs Quickly Resolve Symptoms Associated with EBV-Induced Infectious Mononucleosis in Patients with Atopic Predispositions,” Am. J. Case Rep., vol. 17, p. 84, Feb. 2016, doi: 10.12659/AJCR.895399.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Katarzyna Tłustochowicz, Adrianna Kowalik, Agnieszka Krajewska, Magdalena Korba, Wiktoria Polkowska, Natalia Malicka, Agnieszka Maria Korzeniewska, Julia Agnieszka Dębczak, Karolina Łuczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 43
Number of citations: 0
